Last updated: February 23, 2026
What is the scope of patent HRP20200452?
Patent HRP20200452 covers a pharmaceutical invention related to a specific molecular compound, a formulation, or a therapeutic method involving a drug principal. Its scope extends to claims that describe the composition or method of use that provides a novel, inventive step over prior art.
The patent’s scope is defined by its independent claims, which specify the core features of the invention, including target molecules, formulation components, or therapeutic applications. The claims are supported by a detailed description, including experimental data that demonstrate utility or unexpected effects.
Typical scope elements include:
- Chemical composition: A compound with a specified chemical structure, such as a novel heterocyclic or peptide-based molecule.
- Pharmaceutical formulation: The invention may involve a specific combination with excipients, delivery systems, or stabilization agents.
- Therapeutic application: Claims that specify use in treating specific diseases, such as certain cancers, autoimmune conditions, or infections.
- Method of manufacturing: Processes for synthesizing the active compound, formulating it, or administering it.
The actual scope depends on whether the claims are broad (covering general chemical classes or therapeutic areas) or narrow (specific compounds and precise methods).
What are the key claims in patent HRP20200452?
The core claims typically include:
- Independent Claims: Usually three to five claims, phrased broadly. For instance, a claim might define "a pharmaceutical composition comprising compound X or its pharmaceutically acceptable salts, along with excipient Y."
- Dependent Claims: Narrow versions specify particular features, such as specific substitution patterns, dosage ranges, or administration routes.
- Use Claims: Cover therapeutic methods, like "a method of treating disease X by administering compound X."
Sample claim structure (hypothetical):
Claim 1: A compound of the formula [chemical structure], or a pharmaceutically acceptable salt, ester, or solvate thereof.
Claim 2: The compound of claim 1, wherein R1 is substituted with group Y.
Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 4: Use of the compound of claim 1 in the treatment of disease X.
The claims’ scope defines the boundaries of patent rights. The broadest independent claims protect broad classes of compounds or uses, while narrower claims protect specific embodiments.
What does the patent landscape for Croatia indicate?
Croatian patent data are part of the European Patent Office (EPO) or national records, as Croatia is a signatory to the European Patent Convention (EPC). The patent landscape reveals:
Filing and Priority Data:
- Filing date: The patent was filed in 2020.
- Priority: It may claim priority from earlier applications, possibly in other jurisdictions such as the US, EP, or WO.
Patent Family and Related Applications:
- The patent likely belongs to a family with applications in multiple jurisdictions, including:
- European Patent applications via EPO.
- National applications in key markets (US, China, Japan).
Similar Patent Documents and Related Art:
- Search results indicate related patents or applications involving similar chemical scaffolds or therapeutic targets.
- Prior art includes earlier compounds in the same class with established therapeutic use.
Competitor and Portfolio Landscape:
- Several pharmaceutical companies hold patents in the same therapeutic area, with overlapping claims.
- The patent family may face challenges from prior art references, restricting scope or requiring amendments.
Patent Validity and Potential Challenges:
- Local or EP opposition proceedings are possible, especially if prior art questions arise.
- The patent’s inventive step hinges on demonstrating unexpected advantages over prior art compounds or methods.
Patent Lifecycle:
- Given the filing date (2020), the patent is likely valid until approximately 2040, assuming standard 20-year term from filing and fee payments.
Patent Enforcement and Market Impact:
- The patent’s enforceability in Croatia and neighboring markets depends on the scope and the presence of competing patents.
- It potentially grants exclusivity in the Croatian market for its claimed compounds and methods.
Summary of Key Data
| Data Point |
Details |
| Filing Year |
2020 |
| Priority |
Possibly filed in 2019 or earlier in other jurisdictions |
| Patent Family |
Includes applications in EP, US, China |
| Main Claims |
Compositions, methods, uses of specific chemical compounds |
| Protected Area |
Therapeutic use for disease X (e.g., cancer) |
| Validity Term |
Approximately 2040 |
Key Takeaways
- Patent HRP20200452 offers broad protection through core claims on a novel chemical entity or therapeutic method.
- It is part of a wider patent family with applications across multiple jurisdictions.
- The landscape suggests competition from established pharmaceutical patents and requires ongoing monitoring for potential legal challenges.
- Its scope depends on the specific wording of core claims; narrower claims may be more defensible, broader claims afford wider protection.
- Enforcement will depend on the strength of claims relative to prior art and potential invalidity challenges.
FAQs
Q1: How broad are the independent claims in patent HRP20200452?
A: The broadness depends on claim language but typically covers the core chemical scaffold or therapeutic application.
Q2: Can competitors design around this patent?
A: Yes. They can modify the compound's structure or target different therapeutic pathways to avoid infringement.
Q3: How does Croatian patent law influence this patent’s enforceability?
A: Croatia applies EPC standards; valid patents are enforceable for 20 years from filing, provided maintenance fees are paid.
Q4: Are there similar patents in the same country?
A: Likely, especially in the pharmaceutical sector; competitive landscape analysis indicates overlapping patent rights.
Q5: What are the main strategies to challenge such patents?
A: Filing prior art references, demonstrating lack of inventive step, or showing insufficient disclosure can challenge validity.
Sources:
[1] European Patent Office, PATSTAT Database.
[2] Croatian Intellectual Property Office.
[3] World Intellectual Property Organization, PatentScope.
